Blackstone to Sell Japanese Supplement and OTC Drug Manufacturer Alinamin to MBK for $2.2 Billion
Blackstone is set to sell Alinamin, a prominent Japanese supplement and over-the-counter (OTC) drug manufacturer, to MBK Partners for an estimated $2.2 billion, according to a report by the Nikkei newspaper.

Blackstone is set to sell Alinamin, a prominent Japanese supplement and over-the-counter (OTC) drug manufacturer, to MBK Partners for an estimated $2.2 billion, according to a report by the Nikkei newspaper.
The deal comes after Blackstone acquired Alinamin in 2021. Following the acquisition, Alinamin expanded its operations significantly, including establishing a new unit in Taiwan and increasing its overseas sales. This strategic move aimed to leverage the brand’s strong market presence and expand its footprint beyond the domestic market.
Nikkei highlighted that MBK plans to utilize its expertise in consumer goods acquisitions to further enhance the value of Alinamin. MBK has a proven track record in acquiring and managing consumer-focused businesses, and it aims to capitalize on Alinamin's established reputation in the supplement and OTC drug markets.
The acquisition aligns with MBK's strategy to invest in companies with robust growth potential and strong brand recognition. Alinamin is well-known in Japan for its health supplements and vitamin products, which have a loyal customer base. By integrating Alinamin into its portfolio, MBK aims to drive further growth and expansion, particularly in the Asia-Pacific region.
Since its inception, Alinamin has been a leader in the Japanese supplement market, offering a range of products designed to meet the health and wellness needs of consumers. The company's expansion into international markets under Blackstone's ownership has already shown promising results, with increased sales and market penetration in regions such as Taiwan.
The sale is expected to be completed in the coming months, pending regulatory approvals. This transaction marks another significant milestone for Blackstone as it continues to strategically divest from certain assets while focusing on other growth areas within its vast investment portfolio.
MBK's acquisition of Alinamin is anticipated to bring new opportunities for innovation and market expansion. The partnership aims to enhance the product offerings and reach of Alinamin, leveraging MBK's resources and expertise in consumer goods to build on the brand’s existing success.
This strategic move by MBK underscores the growing interest in the health and wellness sector, particularly in the rapidly expanding markets of Asia. The deal not only reflects MBK's confidence in Alinamin's growth potential but also highlights the ongoing trend of major investment firms seeking to capitalize on the increasing demand for health supplements and OTC drugs.
As the health and wellness industry continues to grow, the acquisition of Alinamin positions MBK to benefit from the rising consumer focus on health and preventative care. With the backing of MBK, Alinamin is well-placed to continue its trajectory of growth and innovation, offering enhanced value to its customers and stakeholders alike.